Flagship Pioneering related stories
All articles and analysis
Under Ballmer's reign at Microsoft, here's the scorecard: 41 VC-backed company acquisitionsIncluded are big deals, such as Skype and Yammer, but plenty of smaller transactions, too
Fund Performance: Mass PRIM Sticks With What’s FamiliarPension fund stays focused on its top, local venture relationships, which include Battery, Spark, TCV, Insight and Union Square
- Flagship Ventures Names Bancel as Senior Partner
Flagship Ventures has named Stephane Bancel as a senior partner. Bancel will also serve as president and CEO of Moderna Therapeutics, a Flagship VentureLabs - founded company. Flagship Ventures, which is based in Cambridge, Mass., is a venture capital firm that focuses on health, therapeutics and sustainability.
- Syros Pharmaceuticals Inks $30M Series A
Syros Pharmaceuticals, which is focused on treatments for cancer and other diseases, has inked $30 million in Series A financing. Company co-founders ARCH Venture Partners and Flagship Ventures led the round. The money will go toward development of novel gene control medicines.
Fund Performance: Clearstone Venture Partners Ranks as CalPERS' Top PerformerThe Santa Monica, Calif.-based firm posted an IRR of 154.7%, as of March 31, 2012
- Avedro Completes $43m Series D
Avedro has completed a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro's other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures. As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the board of directors.
- Blend Therapeutics Calls Up $16M
Blend Therapeutics Inc., a biopharmaceutical company based in Watertown, Mass., has raised $16 million in Series B financing. The company is backed by Flagship Ventures and New Enterprise Associates.
- Moderna Therapeutics Backed by $40M
Cambridge, Mass.-based Moderna Therapeutics has closed on more than $40 million in financing to date, led by Flagship Ventures, the company announced Thursday. The company is developing “messenger RNA Therapeutics.” Moderna was founded within Flagship VentureLabs.